The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC

"The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC" takes up the trial that the panel calls the biggest advance in decades for this setting.

This episode traces small cell lung cancer's slow therapeutic history before turning to the trial that changed it. For roughly three decades, treatment options barely moved: platinum chemotherapy, radiation intensification, and eventually prophylactic cranial irradiation were essentially the only levers available, while several immunotherapy and adjuvant chemotherapy trials in this setting returned negative results. That changed with the ADRIATIC trial, which established consolidation durvalumab as a new standard after concurrent chemoradiation in limited-stage disease. Patients who completed standard chemoradiotherapy were randomized to two years of consolidative durvalumab or placebo, and the trial found a significant reduction in recurrence along with a striking overall survival gain: median survival rose from roughly two to three years with chemoradiation alone to about 55 months, nearly four to five years, with durvalumab added.

Safety proved reassuring. Although thoracic radiation combined with an immune checkpoint inhibitor raises concern for pneumonitis, the trial saw only a modest, non-prohibitive numerical increase, occurring in roughly 20% or fewer of patients. The panel also highlights the trial's inclusive design, which enrolled patients regardless of whether they received prophylactic cranial irradiation and regardless of platinum choice, making the results more directly applicable to routine practice than many landmark trials.

The conversation closes on adherence, since durvalumab consolidation runs a full 24 months. Real-world experience suggests many patients stop closer to seven to nine months, so the panel outlines a proactive approach: baseline and post-chemoradiation pulmonary function testing, monthly rather than biweekly visits to ease the burden, labs checked a week ahead to catch problems early, and close monitoring for pneumonitis risk, which is highest in the first three to six months and greater in patients over 65 and in Asian patients.

Up next, in "Closing the Gap: Underused Consolidation Immunotherapy in Limited-Stage SCLC," the experts confront why so many eligible patients still are not receiving this practice-changing therapy.